Overview of Buclixin

Property	Description
Active ingredient	Buclizine
Form	Tablet or Capsule
Pharmacological class	First-Generation Antihistamine
General purpose	Antiemetic (anti-nausea) and Antivertigo (anti-dizziness)
Origin	Synthetic

1. Defining Buclixin: Active Ingredient and Pharmacological Class

The therapeutic core of the preparation known as Buclixin is the active ingredient, Buclizine (INN). Chemically, Buclizine is a synthetic piperazine derivative, which places it within a distinct chemical group. Pharmacologically, it functions as a first-generation antihistamine because it acts as an H1 histamine receptor antagonist. This classification aligns with its dual action profiles. Buclizine is categorized among the piperazine derivative antihistamines for systemic use. Unlike second-generation antihistamines, the ability of this agent to penetrate the central nervous system is a key differentiating factor, making it suitable for specific neurological applications.

2. Composition, Origin, and Available Forms

The active substance in Buclixin is typically formulated as a stable salt, such as Buclizine dihydrochloride. The agent's origin is synthetic, having been created through chemical manufacture rather than extraction from plant or animal sources. Buclixin is primarily offered for oral administration in tablet or capsule dosage forms. This single-entity drug contains Buclizine as the sole active pharmaceutical ingredient. In certain regional markets, Buclizine is recognized for its antiemetic properties, often positioned for individuals experiencing nausea associated with conditions affecting the inner ear.

3. General Therapeutic Role and Purpose

The primary therapeutic purpose of Buclixin is to act as both an antiemetic (anti-nausea) and an antivertigo (anti-dizziness) medication. The clinical application involves managing dizziness and nausea by acting on specific vestibular pathways in the central nervous system. The drug's dual action—blocking both histamine and acetylcholine receptors—functions to stabilize the pathways responsible for motion perception and the urge to vomit. The general benefit is the symptomatic relief of nausea, vomiting, and feelings of vertigo.

What side effects are possible with Buclixin?

Possible side effects and safety information

The safety profile of Buclizine, the active component of Buclixin, is defined by its classification as a first-generation antihistamine, which carries a known potential for effects on the central nervous and other systems due to its H1-receptor and anticholinergic activities. Official regulatory documents group these potential effects into distinct system-organ classes.

Officially Documented Adverse Reactions

Adverse reactions are predominantly classified across the following systems:

Nervous System Disorders: The most frequently reported reactions involve the central nervous system, including drowsiness, sleepiness, headache, fatigue, and loss of coordination (incoordination).
Gastrointestinal and Anticholinergic Effects: Includes reactions like dry mouth, nausea, vomiting, and blurred vision. Due to its anticholinergic nature, the potential for difficulty in urinating (urinary retention) is noted.
Other Systemic Effects: Reports include increased appetite leading to weight gain, low blood pressure (hypotension), and reactions on the skin such as rash.

Serious Adverse Reactions and Safety Constraints

A serious, though rare, Immune System reaction that has been documented is anaphylactic reaction. The potential for convulsions (seizures) is also noted as a safety consideration, particularly in susceptible patients.

Regulatory documents emphasize the need for caution in specific patient populations. This includes Older Adults, and patients with impaired liver (hepatic) or impaired kidney (renal) function, due to the increased risk of severe adverse effects or drug accumulation. Furthermore, caution is required for individuals with pre-existing conditions like narrow-angle glaucoma, asthma, or prostatic enlargement due to the drug’s known properties. The concurrent use of Buclizine with other Central Nervous System (CNS) depressants, including alcohol, may lead to increased CNS depression.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Buclixin as a medical emergency primarily characterized by serious effects on the central nervous system (CNS) and the heart. A suspected overdose requires immediate professional intervention.

Documented Overdose Presentations

The most common manifestation of overdosage is hypersedation (extreme drowsiness). Other reported CNS presentations include stupor, convulsions, and involuntary motor activity. Gastrointestinal effects such as nausea and vomiting have also been reported.

Critical Cardiovascular Risks

Overdose may cause significant cardiac complications, including QT prolongation, which is an abnormality in the heart's electrical cycle, and Torsade de Pointes, a dangerous, fast, and irregular heart rhythm. Due to the risk of potentially fatal arrhythmias, continuous electrocardiogram (ECG) monitoring is required in a healthcare setting.

Overdose Management

There is no specific antidote available to reverse the effects of an overdose. The management of overdosage is strictly supportive and focused on maintaining the airway, observing vital signs closely, and stabilizing the patient. Measures to reduce drug absorption, such as gastric lavage or induction of vomiting, may be considered. Hypotension should be treated with intravenous fluids and appropriate vasopressors, excluding epinephrine. Hemodialysis is considered doubtful for effectively removing the drug from the body. All suspected cases of overdosage require immediate medical assessment and professional intervention.

Therapeutic Uses of Buclixin

What Buclixin Treats: Main Uses and Benefits

Buclixin may be applied in managing symptoms related to systemic imbalance and inner ear disturbances. Buclixin is commonly used to help address symptom clusters that may become intense or disruptive, such as nausea, vomiting, and symptoms of dizziness. It is also used for easing symptoms related to inflammatory or irritative states typical of allergic reactions, such as sneezing and itching.

This therapeutic support is generally applied in contexts where short-term symptomatic assistance is needed, such as during travel or episodes of sudden symptom escalation. This benefit contributes to easing the overall symptom load and supports a sense of stability when symptoms are more noticeable.

“Buclixin assists patients during difficult episodes by helping ease the overall symptom burden associated with motion and balance challenges.”

Quick Fact: Relief for Vertigo

Quick Fact: Relief for Vertigo and Nausea is generally considered the primary therapeutic focus, supporting a sense of stability and contributing to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Regulatory authorities define who can and cannot use Buclixin based on age, physiological status, and pre-existing medical conditions, establishing strict eligibility rules that must be followed. These rules are documented in the official prescribing information for the active ingredient, Buclizine.

Absolute Contraindications

Population	Status Defined by Regulators
Children under 12 years	Contraindicated
Breastfeeding Women	Contraindicated
Hypersensitivity	Contraindicated (to Buclizine or excipients)

Conditional Use and Restrictions

Use of Buclixin is permitted in adults and adolescents aged 12 years and older, but certain conditions require the medication to be administered with caution or may necessitate a restriction of use:

Impaired Organ Function: Caution is required for patients with pre-existing hepatic or renal impairment.
Anticholinergic-Sensitive Conditions: Use requires caution in patients with glaucoma, prostatic hypertrophy (enlarged prostate), or urinary retention due to the drug's properties.
Pregnancy: The medication is not recommended for use in pregnancy unless a physician determines the benefit to the mother outweighs the potential risk to the fetus, as safety data are insufficient.
The Elderly: Use requires caution, particularly in frail patients, reflecting the higher prevalence of decreased organ function in this age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Buclixin primarily around pharmacodynamic effects resulting from its properties as a sedating H1-antihistamine with anticholinergic activity. These interactions are categorized based on their resulting clinical effects, requiring cautious co-administration or strict avoidance.

Documented Interaction Categories

Interaction Type	Interacting Product Categories
Additive CNS Depression	Other CNS Depressants (e.g., opioids, benzodiazepines)
Potentiated Anticholinergic Effects	Other Antimuscarinic Drugs (e.g., tricyclic antidepressants)
Effect Enhancement	Alcohol

Specific Interaction Constraints

Co-administration with alcohol is explicitly restricted due to its potential to significantly enhance the sedative effects of Buclixin. Concurrent use with other drugs classified as CNS depressants may result in additive sedation and increased central nervous system depression. Similarly, co-administration with other antimuscarinic agents may potentiate peripheral anticholinergic effects, such as urinary retention or dry mouth.

In a procedural context, regulatory information notes that prior administration of Buclixin may decrease the emetic response elicited by the therapeutic or diagnostic agent Apomorphine. No specific timing separation requirements are defined in the official labeling for co-administered drugs.

Mechanism of Action

Buclixin is a piperazine-derivative molecule that acts as a non-competitive antagonist at two primary receptor systems within the central nervous system (CNS), specifically targeting the chemoreceptor trigger zone (CTZ) and the vomiting center in the medulla. Its principal molecular targets are the Histamine H1 receptors and Muscarinic acetylcholine receptors ( M1). Buclixin competitively binds to and blocks the H1 receptor, preventing the endogenous agonist, histamine, from initiating signal transduction via this G-protein coupled receptor (GPCR). Simultaneously, it acts as an anticholinergic agent by blocking the M1 receptors in the CNS. The consequence of this dual receptor antagonism is a modulation of neuronal excitability. By reducing the signaling of both the histaminergic and cholinergic pathways that transmit stimuli from the vestibular apparatus and the circulation to the vomiting center, Buclixin depresses labyrinthine excitability and central vestibular stimulation. This intracellular blockade results in the reduction of overall afferent activity to the vomiting center, leading to a system-level physiological modulation characterized by a decrease in the response to emetic stimuli.

Dosage and Administration Information

How to Use Buclixin: General Administration Guidelines

Buclixin (Buclizine) is administered according to standard guidelines specifying the route, dose, frequency, and duration of use. These instructions are designed to standardize the administration process.

Approved Route and Forms

Buclixin is approved for oral administration and is typically available in the form of a tablet or capsule. In certain combination products, the Buclizine component is formulated for oral use, such as a film-coated tablet.

Labeled Dosing and Schedule

Administration details are governed by the specific indication, with standard regimens:

Standard Single Dose: For motion sickness prevention, the usual dose is 25 mg to 50 mg of Buclizine, taken as a single dose.
Timing: The initial dose for prophylaxis should be administered approximately 30 minutes before travelling.
Re-dosing: If further relief is necessary during travel, the dose may be repeated after 4 to 6 hours, subject to maximum limits.
Maximum Limit: For combination products containing 6.25 mg Buclizine, the maximum dose is restricted to 8 tablets in 24 hours.

Contextual and Population-Specific Instructions

Standard guidelines provide context for proper intake and necessary dose modifications:

Instruction Domain	Guidance	Functional Note
Timing with Food	Often advised to be taken with meals or immediately after food.	Aids proper intake.
Use Duration	Intended for short-term use; continuous use for longer than 3 days requires medical review.	Limits duration of administration.
Older Adults	Normal adult dosage is typically appropriate, but caution and potential dose reduction are advised in the presence of renal or hepatic impairment.	Guides population adjustment.

These instructions define the standardized, procedural structure for administering the medicine, including dosage and frequency.

Recent Clinical Evidence

Research evidence / Overview of studies for Buclixin

Evidence for Antivertigo and Motion Sickness

This section will summarize the research base for Buclixin's study in symptoms of vertigo and its study as a potential intervention for motion sickness, detailing the types of historical clinical trials and comparator studies available.

The research was studied for conditions characterized by fluctuating or episodic manifestations of dizziness and motion intolerance. The evidence includes historical clinical trials, primarily utilizing Randomized Controlled Trials (RCTs) and double-blind designs, often comparing Buclixin against placebo or other agents studied for similar symptoms. Studies monitored outcomes related to systemic or functional imbalance, such as patient-reported severity scores for vertigo episodes. Findings describe patterns observed in the studies over short observation intervals. Certainty remains low regarding these findings in the context of current treatment standards, as the research base is derived from studies conducted decades ago.

Evidence for Antiemetic (Nausea and Vomiting Relief)

This part will outline the historical studies and scientific reviews that have evaluated the anti-nausea and anti-vomiting properties of the agent, focusing on the various study designs and outcomes measured by researchers.

Buclixin was evaluated in trials focused on its anti-nausea and anti-vomiting capabilities. Researchers examined outcomes related to physical discomfort and outcomes describing episodic or acute changes, such as the frequency of vomiting episodes and the intensity of perceived nausea. Studies involved patient-reported outcomes describing perceived discomfort. The available data are still emerging regarding the consistency and contemporary relevance of these findings. Because the research is largely historical, results apply only to the populations studied and under the specific conditions of those older trials.

Research on Use in Allergic Symptom Relief

Research examined Buclixin within its pharmacological classification as a first-generation antihistamine, focusing on its ability to affect outcomes linked to inflammatory or irritative states for symptoms observed in allergic states. Studies explored short-term symptom patterns by monitoring changes in scores for typical allergic complaints such as sneezing and nasal congestion. Evidence is limited because the findings often derive from the general pharmacological effects of the H1-antihistamine drug class, rather than contemporary large-scale clinical trials focused specifically on Buclizine.

Long-Term Evidence and Durability of Response

There is limited information for long-term outcomes regarding the agent's effects. Long-term effects are not fully established, and there is a lack of evidence describing the durability of the observed responses over extended periods of administration.

Key Studies & References R06AE Piperazine derivatives - WHO Collaborating Centre for Drug Statistics Methodology (ATC Index)

Frequently Asked Questions (FAQ)

Common questions about Buclixin (FAQ)

Q: What is the main medical purpose of Buclixin as described in official documents?

Official regulatory-linked information describes Buclixin as indicated for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo. These indications are described in official regulatory information.

Q: Is Buclixin officially classified as an antihistamine?

Yes, Buclixin is officially classified as an antihistamine, specifically belonging to the piperazine derivative class. Its action is based on blocking the Histamine H1 receptors.

Q: What specific conditions, besides motion sickness, is Buclixin described as treating?

In addition to motion sickness, official product information lists Buclixin for conditions including vertigo (a feeling of spinning or dizziness), nausea, and vomiting. These conditions are included in the regulatory-defined therapeutic uses.

Q: Why do some people refer to Buclixin as an appetite stimulant?

Although Buclixin has historically been discussed or promoted for increasing appetite, regulatory-linked information states that this specific use has not been validated. The officially supported purpose is focused on motion sickness and vertigo symptoms.

Q: Is the use of Buclixin for appetite stimulation considered an approved indication?

Regulatory-linked sources indicate that the appetite stimulant effect is not a validated or approved indication for Buclixin. Official use primarily addresses the treatment of nausea, vomiting, and dizziness.

Q: Has the regulatory status of Buclixin for increasing appetite changed recently?

Regulatory commentary suggests the appetite stimulant use remains unvalidated and is not supported by sufficient evidence according to official standards. The primary regulatory authorization covers its antihistamine and anti-vertigo properties.

Q: Are there any official warnings about taking Buclixin for weight gain?

Regulatory documents do not provide warnings or guidance specifically for the unvalidated use of the medication. Official regulatory bodies focus their guidance only on approved indications.

Q: What are the most common side effects of Buclixin listed in official sources?

Due to its mechanism as an anticholinergic and central nervous system (CNS) depressant, expected side effects may include somnolence (drowsiness), dizziness, and dry mouth. Official product information lists potential effects based on the drug's known action.

Q: Is drowsiness a common or major expected side effect of Buclixin?

Buclixin has central nervous system (CNS) depressant properties. This is the underlying mechanism that leads to the potential for experiencing drowsiness or somnolence.

Q: Why is Buclixin associated with dry mouth, and what is the cause?

The dry mouth is a result of Buclixin’s action as an anticholinergic agent. This means it blocks muscarinic acetylcholine receptors ( M1), which are involved in the process of saliva production.

Q: Are there risks associated with operating machinery after taking Buclixin?

Due to the potential for dizziness and drowsiness from its CNS depressant effects, the ability to perform skilled tasks such as driving or operating machinery may be impaired. Official guidance advises caution related to tasks requiring mental alertness.

Q: Does Buclixin cause dizziness, and what should be known about that symptom?

Dizziness is listed both as a condition Buclixin treats (vertigo) and as a potential effect of its CNS depressant properties. Information indicates that caution related to impaired mental alertness is a general safety measure when this effect occurs.

Q: Can Buclixin affect the ability to concentrate, according to official information?

As a central nervous system (CNS) depressant, Buclixin's mechanism suggests a potential for effects on mental alertness and concentration. This is related to the drug's overall sedating properties.

Q: What groups of people are listed as needing to use Buclixin with caution?

Beyond the specific caution advised for older adults with renal or hepatic impairment, its anticholinergic properties typically require caution in individuals with conditions such as prostate problems or certain types of glaucoma. This is based on the drug's class effects.

Q: Is Buclixin use restricted for patients with a history of glaucoma?

Due to Buclixin's anticholinergic properties, its use is generally advised against in individuals with narrow-angle glaucoma, consistent with the safety profile of this drug class.

Q: Are there any known issues with taking Buclixin alongside alcohol?

As Buclixin is described as a central nervous system (CNS) depressant, consuming alcohol alongside the drug may result in an increased risk of sedation and other CNS side effects.

Q: What types of CNS depressant medications can interact with Buclixin?

Buclixin's central nervous system (CNS) depressant properties mean that interactions are likely with other substances that also cause CNS depression. This includes sedatives, hypnotics, tranquilizers, and certain analgesics.

Q: Does Buclixin have anticholinergic properties that lead to drug interactions?

Yes, Buclixin is described as an anticholinergic agent. This property can lead to additive side effects and interactions when the drug is used with other anticholinergic medicines.

Q: What should a patient know about taking Buclixin with other antihistamines?

Since Buclixin is an H1 antagonist, combining it with other antihistamines may lead to increased side effects. This is primarily due to the increased potential for central nervous system depression, dizziness, and sedation.

Q: Does Buclixin interact with medicines used to treat depression or anxiety?

Due to its central nervous system (CNS) depressant effects, Buclixin may interact with certain medicines for depression or anxiety that also cause CNS depression or sedation. These potential interactions are a result of additive effects on the central nervous system.

Q: Are there special considerations for using Buclixin in the elderly population?

In addition to the dose considerations for organ impairment, caution is generally advised in the elderly due to increased sensitivity to anticholinergic effects and CNS depression. This increased sensitivity can raise the risk of dizziness and falls.

Q: Why is Buclixin sometimes used for allergy symptoms like itching or hives?

Buclixin is an H1 antagonist. This class of drug is commonly used because it blocks histamine, which is the chemical responsible for causing symptoms like itching, watery eyes, and hives.

Q: Is Buclixin classified as a steroid?

No, Buclixin is not classified as a steroid. It is officially identified as a piperazine-derivative antihistamine based on its chemical structure and primary mechanism of action.

Q: Are there official research summaries discussing the efficacy of Buclixin?

The drug was initially approved by the FDA in 1957. The current approval for its listed indications is supported by the research evidence that was submitted for that initial authorization.

Q: What do researchers say about the evidence supporting Buclixin's effectiveness for its main uses?

The effectiveness of Buclixin for its approved uses is based on the evidence reviewed by regulatory bodies that led to its initial market approval. Official information indicates the evidence provided was sufficient for its approval for the listed indications.

Q: Is it normal to feel a little sleepy after taking Buclixin?

Given Buclixin is classified as a central nervous system (CNS) depressant, experiencing some sleepiness is a known potential effect. This is directly linked to its mechanism of action on the brain.

Q: Why does Buclixin block histamine, and what does this chemical do?

Buclixin blocks histamine to prevent this chemical from activating its receptors. This action reduces symptoms like nausea, dizziness, and allergy symptoms that can be triggered by histamine release in the body.

How should Buclixin be stored and disposed of?

How to Store and Dispose of Buclixin

Official regulatory documents define specific conditions for storing and disposing of this medicine to ensure stability and safety.

Storage Requirements

Buclixin must be kept at a controlled temperature. Labeled instructions state that the medicine must not be stored above 30 C. The product is typically supplied in blister packaging, which helps protect the tablets from moisture.

Storage Constraint	Requirement as Stated in Label
Temperature Limit	Do not store above 30 C
Shelf-Life	Shelf life is 3 years; do not use after the expiry date
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

The medicine must not be thrown away with household trash or via wastewater (such as flushing down a toilet). Official guidance requires consulting a pharmacist for instructions on how to properly dispose of unused or expired Buclixin to ensure correct environmental protection.

Buclixin